Quadrivalent meningococcal conjugated vaccine: A routine or selective vaccine in Europe?

Journal of Infection

Volumn 65, Issue 3, 2012, Pages 193-196

  Masuet Aumatell, Cristina ^a   Borrow, Ray ^b   Zuckerman, Jane N ^c  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA TOXOID; MENINGOCOCCUS VACCINE;

BACTERIAL STRAIN; BACTERIAL TRANSMISSION; BACTERIAL VIRULENCE; BACTERIUM CARRIER; EDITORIAL; ENDEMIC DISEASE; EPIDEMIC; EUROPE; HERD IMMUNITY; IMMUNOGENICITY; INCIDENCE; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; PUBLIC HEALTH PROBLEM; VACCINATION;

EPIDEMICS; EUROPE; HUMANS; IMMUNIZATION PROGRAMS; IMMUNIZATION SCHEDULE; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; VACCINES, CONJUGATE;

EID: 84864540386     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2012.04.008     Document Type: Editorial

References (26)

1. Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices Updated recommendations for use of meningococcal conjugate vaccines - Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep 2011 Jan 28, 60(3):72-76.
2. Teyssou R., Muros-Le Rouzic E. Meningitis epidemics in Africa: a brief overview. Vaccine 2007, 25(Suppl. 1):A3-A7.
3. World Health Organization International travel and health 2011 2011, WHO, Geneva, p. 176-177 [Chapter 9].
4. Harrison L.H. Prospects for vaccine prevention of meningococcal infection. Clin Microbiol Rev 2006, 19:142-164.
5. Kelly D.F., Pollard A.J., Moxon E.R. Immunological memory: the role of B cells in long-term protection against invasive bacterial pathogens. JAMA 2005, 294:3019-3023.
6. Harrison L.H., Trotter C.L., Ramsay M.E. Global epidemiology of meningococcal disease. Vaccine 2009, 27(Suppl. 2):B51-B63.
7. Miller E., Salisbury D., Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine 2001 Oct 15, 20(Suppl. 1):S58-S67.
8. Ramsay M.E., Andrews N.J., Trotter C.L., Kaczmarski E.B., Miller E. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ 2003, 326:365-366.
9. Maiden M.C., Ibarz-Pavón A.B., Urwin R., Gray S.J., Andrews N.J., Clarke S.C., et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis 2008 Mar 1, 197(5):737-743.
10. Auckland C., Gray S., Borrow R., Andrews N., Goldblatt D., Ramsay M., et al. Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom. J Infect Dis 2006, 194:1745-1752.
11. Ladhani S.N., Lucidarme J., Newbold L.S., Gray S.J., Carr A.D., Findlow J., et al. Increase in invasive meningococcal capsular group Y disease in England and Wales. Emerg Infect Dis 2012, 18:63-70.
12. Joint Committee on Vaccination and Immunisation Meningococcal subcommittee report, 18th February 2011 2011, [Visited the 3rd of February 2012], Department of Health, UK, Available at:. http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@ab/documents/digitalasset/dh_128724.pdf.
13. Joint Committee on Vaccination and Immunisation The use of meningococcal C vaccines in the routine childhood immunisation programme, 29th January 2012 2012, [Visited the 3rd of February 2012], Department of Health, UK, Available at:. http://www.dh.gov.uk/ab/JCVI/DH_094744.
14. EMA. Summary of product information Menveo (last time visited 4th of November 2011 at: ). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR-Product_Information/human/001095/WC500090147.pdf.
15. Immunisation against infectious disease, The Green book. Meningococcal. [accessed 05.11.11] [Chapter 22]. mailto:http://www.dh.gov.uk/dr_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_125942.pdf.
16. Jokhdar H., Borrow R., Sultan A., Adi M., Riley C., Fuller E., et al. Immunologic hyporesponsiveness to serogroup C but not serogroup A following repeated meningococcal A/C polysaccharide vaccination in Saudi Arabia. Clin Diagn Lab Immunol 2004 Jan, 11(1):83-88.
17. Al-Mazrou Y., Khalil M., Borrow R., Balmer P., Bramwell J., Lal G., et al. Serologic responses to ACYW135 polysaccharide meningococcal vaccine in Saudi children under 5 years of age. Infect Immun 2005 May, 73(5):2932-2939.
18. Salleras L., Domínguez A., Cardeñosa N. Dramatic decline of serogroup C meningococcal disease in Catalonia (Spain) after a mass vaccination campaign with meningococcal conjugate vaccine. Vaccine 2003, 1(7-8):729-733.
19. Ramsay M.E., Andrews N., Kaczmarski E.B., Miller E. Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England. Lancet 2001, 357:195-196.
20. Hershey J.H., Hitchock Epidemiology and meningococcal serogroup distribution in the United States. Clin Pediatrics 2010, 49:519-524.
21. Bilukha O.O., Rosenstein N. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2005, 54(RR-7):1-21.
22. Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices Licensure of a meningococcal conjugate vaccine for children aged 2 through 10 years and updated booster dose guidance for adolescents and other persons at increased risk for meningococcal disease-Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep 2011 Aug 5, 60(30):1018-1019.
23. Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices Recommendation of the Advisory Committee on Immunization Practices (ACIP) for use of quadrivalent meningococcal conjugate vaccine (Men ACWY-D) among children aged 9 through 23 months at increased risk for invasive meningococcal disease. MMWR Morb Mortal Wkly Rep 2011 Oct 14, 60(40):1391-1392.
24. Harrison L.H., Jolley K.A., Shutt K.A., Marsh J.W., OLeary M., Sanza L.T., et al. Antigenic shift and increased incidence of meningococcal disease. J Infect Dis 2006, 193:1266-1274.
25. Kristiansen P.A., Diomandé F., Wei S.C., Ouédraogo R., Sangaré L., Sanou I., et al. Baseline meningococcal carriage in Burkina Faso before the introduction of a meningococcal serogroup A conjugate vaccine. Clin Vaccine Immunol 2011 Mar, 18(3):435-443.
26. Meningitis vaccine project. News Digest 4th quarter 2011, 31. Visited the 3rd of February 2012., Available at:. http://www.meningvax.org/files/MVPnewsdigest_2011_Q4_31_EN.pdf.